多肽CRDMO新贵”泰德医药(3880.HK)今日首日在港挂牌上市，盘初一度涨近4%报31.8港元；该股IPO定价30.6港元，每手100股，公开发售获301.15倍认购。 据弗若斯特沙利文资料显示，2023年，按销售收入计，泰德医药是全球第三大专注于多肽的CRDMO，市场份额为1.5%。公司也是全球专注于多肽的最全面的CRDMO之一，提供从早期发现、临床前研究及临床开发以至商业化生产的全周期服务。 财务数据方面，公司2022年-2024年收益分别为人民币3.51亿元、人民币3.37亿元及人民币4.42亿元；同期毛利分别为人民币2.01亿元、人民币1.80亿元及人民币2.49亿元；年内利润分别为人民币5398万元、人民币4890.5万元及人民币5917.3万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.